1st July 2022

Celix Pharma announces the launch of Pirfenidone Tablets

Celix Pharma is excited to announce the launch of Pirfenidone 267mg, 801mg Film-coated Tablets in the UK.  The 267mg is available in blister packs of 63 and 252 tablets, whereas the 801mg is available in a blister pack of 84 tablets.  

Pirfenidone is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a rare, chronic and progressive lung disease caused by scarring in the lungs. There are currently no treatment options that stop or reverse IPF and the current treatment focuses on slowing the rate of scarring in the lungs and controlling symptoms. Pirfenidone is one of the few treatment options available for patients with IPF (1). 

Commenting on this launch, Subir Kohli, Co-founder & CEO said, “As our first product launch in the secondary-care segment, Pirfenidone represents another significant milestone for Celix Pharma. To make it easy for patients to get access to this critical medicine, Celix is offering a homecare service supplying the product directly to patients’ home, in addition to making the product available through hospital pharmacy.”  

Shantreddy Soogareddy, Co-founder & COO added “Pirfenidone is first of several products for hospital pharmacy that Celix is launching in 2022, as we continue to build on our plans of having presence across both the retail and hospital channels”. 

1 Source: British Lung Foundation (https://www.blf.org.uk/)